Rocket Pharmaceuticals, Inc. (RCKT) Earnings History
Annual and quarterly earnings data from 2012 to 2025
Loading earnings history...
RCKT EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
RCKT Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
Download Data
Export RCKT earnings history in CSV or JSON format
Free sign-in required to download data
Rocket Pharmaceuticals, Inc. (RCKT) Earnings Overview
As of May 8, 2026, Rocket Pharmaceuticals, Inc. (RCKT) reported trailing twelve-month net income of -$223M, reflecting +26.4% year-over-year growth. The company earned $-2.01 per diluted share over the past four quarters.
Looking at the long-term picture, RCKT's historical earnings data spans multiple years. The company achieved its highest annual net income of -$6M in fiscal 2012.
Rocket Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including CRSP (-$569M net income, -16569.8% margin), EDIT (-$160M net income), BEAM (-$65M net income, -57.2% margin), RCKT has comparable earnings metrics. Compare RCKT vs CRSP →
RCKT Earnings vs Peers
Earnings metrics vs comparable public companies
RCKT Historical Earnings Data (2012–2025)
14 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$223M | +13.8% | -$232M | $-2.01 | - | - |
| 2024 | -$259M | -5.4% | -$273M | $-2.73 | - | - |
| 2023 | -$246M | -10.7% | -$260M | $-2.92 | - | - |
| 2022 | -$222M | -31.2% | -$224M | $-3.26 | - | - |
| 2021 | -$169M | -15.3% | -$167M | $-2.68 | - | - |
| 2020 | -$147M | -76.2% | -$136M | $-2.52 | - | - |
| 2019 | -$83M | -11.7% | -$76M | $-1.70 | - | - |
| 2018 | -$75M | -152.6% | -$71M | $-1.89 | - | - |
| 2017 | -$29M | +31.2% | -$27M | $-4.36 | - | - |
| 2016 | -$43M | +37.0% | -$42M | $-6.41 | - | - |
See RCKT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RCKT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare RCKT vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonRCKT — Frequently Asked Questions
Quick answers to the most common questions about buying RCKT stock.
Is RCKT growing earnings?
RCKT EPS is $-2.01, with earnings growth accelerating to +26.4%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-223M.
What are RCKT's profit margins?
Rocket Pharmaceuticals, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are RCKT's earnings?
RCKT earnings data spans 2012-2025. The accelerating earnings trend is +26.4% YoY. Historical data enables comparison across business cycles.